$HROW News
Last published 1d ago
- 1d agoHROWHarrow Third Quarter 2026 Earnings Conference Call - HARROW INCEarnings Call TranscriptsGood morning, and welcome to HARO 3rd Quarter 2026 Earnings Conference Call. My name is Michelle, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will con
- 2d agoHROWHARROW, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2d agoHROWHarrow Announces Third Quarter 2026 Financial ResultsGlobeNewswireThird Quarter 2026 and Selected Highlights:
- 2d agoHROWHarrow Announces Third Quarter 2026 Financial ResultsGlobeNewswireThird Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over yearBranded revenue of $83.5 million, up 62% year over year and approximately 84% of
- 1w agoHROWHarrow Launches HarrowRx PlatformGlobeNewswireNASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescribing and
- 2w agoHROWHarrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026GlobeNewswireNASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for
- 2mo agoHROWHarrow to Participate in Three Investor Conferences in SeptemberGlobeNewswireNASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the
- 2mo agoHROWHarrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal InjectionsGlobeNewswireNASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective,
- 3mo agoHROWHarrow Second Quarter 2026 Earnings Conference Call - HARROW INCEarnings Call TranscriptsGood morning and welcome to HERO's second quarter 2026 earnings conference call. My name is Michelle and I will be the operator for today's call. At this time, all participants are in a listen-only mode. Later, we will c
- 3mo agoHROWHarrow Announces Second Quarter 2026 Financial ResultsGlobeNewswireSecond Quarter 2026 and Selected Highlights: Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over yearReiterated full-year 2026 financial guidance of $350 million to $365 million in
- 3mo agoHROWHarrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye DiseaseGlobeNewswireNASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement
- 3mo agoHROWHarrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026GlobeNewswireNASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for
- 3mo agoHROWSamsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026GlobeNewswireA real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumabIn treatment-naïve patients, SB11 provided functional and anatomical
- 3mo agoHROWHarrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual MeetingGlobeNewswireNASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting
- 4mo agoHROWHarrow Announces Commercial Launch of BYOOVIZ® in the United StatesGlobeNewswireNASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ®
- 4mo agoHROWSamsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with HarrowBusiness WireIn July 2025, Samsung Bioepis entered into partnership with Harrow for commercialization of two interchangeable ophthalmology biosimilars — BYOOVIZ® (ranibizumab-nuna) and OPUVIZ™ (aflibercept-yszy) — in the
- 5mo agoHROWHarrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric EyecareGlobeNewswireVERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriersVERKAZIA is indicated
- 5mo agoHROWHarrow to Present at William Blair's 46th Annual Growth Stock ConferenceGlobeNewswireNASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair's
- 6mo agoHROWHROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law ViolationsGlobeNewswireMONSEY, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Harrow, Inc. (NASDAQ:HROW) ("HROW") has violated the federal securities laws after the company advised
- 6mo agoHROWHarrow Announces First Quarter 2026 Financial ResultsGlobeNewswireFirst Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category)VEVYE demand growth on track
- 6mo agoHROWHarrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026GlobeNewswireNASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for
- 6mo agoHROWHarrow Announces the Issuance of J-Code for IOPIDINE® 1%GlobeNewswireNASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE® 1% (apraclonidine
- 7mo agoHROWLogiCare3PL Selected as Distribution Partner by HarrowPR NewswireLogiCare3PL today announced it has been selected by Harrow, Inc. (Nasdaq: HROW) as a distribution partner for Harrow's portfolio of ophthalmic...
- 7mo agoHROWHarrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030GlobeNewswireNASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the
- 7mo agoHROWHarrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support GrowthGlobeNewswireNASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market
- 8mo agoHROWHarrow to Present at Leerink Partner's 2026 Global Healthcare ConferenceGlobeNewswireNASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink
- 8mo agoHROWHarrow Fourth Quarter 2025 Earnings Conference Call - HARROW INCEarnings Call TranscriptsGood day and welcome to the HARO fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. Please
- 8mo agoHROWHarrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery IndicationGlobeNewswireNASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug Administration
- 8mo agoHROWHarrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial GuidanceGlobeNewswireFourth Quarter, Full-Year 2025 and Selected Highlights: Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase
- 8mo agoHROWHarrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026GlobeNewswireNASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for
- 8mo agoHROWHarrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ KitsGlobeNewswireNASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber (DTP)
- 9mo agoHROWOSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in CaliforniaBusiness WireThe Montana-based compounder commits to supporting prescribers and patients in wake of competitor's abrupt exit of California market OSRX, Inc., a leading provider of compounded ophthalmic medications, announced that
- 9mo agoHROWHarrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong GrowthGlobeNewswireDoubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is
- 11mo agoHROWHarrow to Present at Two Investor Conferences in DecemberGlobeNewswireNASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the
- 11mo agoHROWHarrow Announces Closing of Acquisition of Melt PharmaceuticalsGlobeNewswireNASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt
- 1y agoHROWHarrow Third Quarter 2025 Earnings Conference Call - HARROW INCEarnings Call TranscriptsGood day, and welcome to the HARO Third Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Instru
- 1y agoHROWHarrow Announces Third Quarter 2025 Financial ResultsGlobeNewswireThird-Quarter 2025 and Recent Selected Highlights: Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year periodGAAP net income of $1.0 millionAdjusted EBITDA of $22.7 millionCash
- 1y agoHROWHarrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025GlobeNewswireNASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for
- 1y agoHROWImprimisRx Announces Leadership ChangesGlobeNewswireFrank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of
- 1y agoHROWHarrow to Acquire Melt PharmaceuticalsGlobeNewswireNASHVILLE, Tenn., Sept.
- 1y agoHROWHarrow Launches Harrow Access for All (HAFA)GlobeNewswireHAFA to Expand Harrow's Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal
- 1y agoHROWHarrow Announces Agenda and Speakers for Investor & Analyst DayGlobeNewswireNASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor &
- 1y agoHROWHarrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030GlobeNewswireNASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the
- 1y agoHROWHarrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030GlobeNewswireAnnounces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) --
- 1y agoHROWHarrow, Inc. (HROW) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoHROWHarrow Announces Second-Quarter 2025 Financial ResultsGlobeNewswireSecond-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash
- 1y agoHROWHarrow to Present at H.C. Wainwright 5th Annual Ophthalmology ConferenceGlobeNewswireNASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright's 5th Annual
- 1y agoHROWHarrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025GlobeNewswireNASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended
- 1y agoHROWHarrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United StatesBusiness WireHarrow to assume full commercial responsibility for BYOOVIZ® and OPUVIZ™ by the end of 2025 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it has
- 1y agoHROWSamsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United StatesBusiness WireHarrow will assume full commercial responsibility for BYOOVIZ® (ranibizumab-nuna) and OPUVIZ™ (aflibercept-yszy) upon full transition of Biogen's commercialization rights back to Samsung Bioepis by the end